Clinical trials: Sweat
Primary Axillary Hyperhidrosis
A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis
This is a prospective, multi-center, randomized, double-blinded study. Subjects enrolled will be randomly assigned to receive either active treatments for axillary hyperhidrosis with the Ulthera System in both axillas, or sham…
- Trial name
- NCT01722461
- Testing
- Ulthera System
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ulthera, Inc
Hyperhidrosis
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02336503
- Testing
- BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 189 people
- Sponsor
- Botanix Pharmaceuticals
Psoriasis, Eczema/Atopic Dermatitis
Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases
Psoriasis, atopic dermatitis (eczema) and hidradenitis suppurativa are long-term skin conditions that flare and settle over time. Most of what happens to the skin happens at home, between hospital appointments.
- Conditions
- Psoriasis, Eczema/Atopic Dermatitis, Hidradenitis Suppurativa (HS)
- Trial name
- Skin-in-Sight (NCT07804134)
- Where
- 3 sites in Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Medisch Spectrum Twente
Cystic Fibrosis
A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor
Cystic Fibrosis (CF) is a hereditary multi-system disease affecting approximately 30,000n children and adults in the USA. The diagnosis of CF requires biochemical confirmation (either abnormal sweat chloride measurement and/or…
- Trial name
- NCT03367494
- Testing
- Measurement of Sweat Chloride and Sweat Bromide
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Fluid Intake in Athletes, Sweating Rate in Athletes
Validity of Smart Cap and Smart Sweat Patch
The main objectives are to determine the validity of a Smart Cap in measuring fluid intake during running and fitness exercise and the validity of a Smart Sweat Patch in measuring sweat rate and sweat chloride concentration…
- Conditions
- Fluid Intake in Athletes, Sweating Rate in Athletes, Sweat Chloride Concentration in Athletes
- Trial name
- NCT04920266
- Testing
- Smart Cap, running and fitness exercisers only, Sweat Patch, all subjects- running, fitness, cycling, Reference sweat patch, all subjects - running, fitness, cycling
- Where
- 3 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Hidradenitis Suppurativa (HS)
Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
The objective of this study is to evaluate the long-term safety and effectiveness of Humira in patients with Hidradenitis Suppurativa (HS) in real-world clinical practice in Japan.
- Trial name
- NCT03894956
- Where
- 37 sites in Japan
- Volunteers
- 46 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.
Hidradenitis Suppurativa (HS) is a severe, chronic debilitating disease with a variable and incomplete response to current treatments.
- Trial name
- NCT04084665
- Testing
- Guselkumab
- Where
- United States
- Sponsor
- Rockefeller University
Hidradenitis Suppurativa
Treatment of Moderate Hidradenitis Suppurativa
The study will be conducted over 24 weeks on active therapy followed by a four-week observational visit. The total length of the study will be 28 weeks.
- Trial name
- NCT03910803
- Testing
- Brodalumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Florida Academic Dermatology Centers
Hidradenitis Suppurativa
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- NCT06921850
- Testing
- Bimekizumab
- Where
- 16 sites in United States, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.
- Trial name
- HB0043-HS-0-01 (NCT06895499)
- Testing
- HB0043
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Hidradenitis, Healthy Volunteers
SAR447971 First-in-human Study
SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation.
- Trial name
- NCT07629336
- Testing
- SAR447971
- Where
- Netherlands
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hidradenitis Suppurativa
Regulation of Inflammatory Genes in Hidradenitis Suppurativa
The purpose of this protocol is to examine the cytokine profi le of pati ents with hidradeniti s suppurati va (HS) and idemechanisms responsible for post-transcripti onal regulati on of these genes.
- Trial name
- NCT05507125
- Testing
- Mental health
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Alabama at Birmingham
Hot Flashes
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
Hot flashes and night sweats (also known as vasomotor symptoms or VMS) are the most common symptoms which bother women in menopause.
- Trial name
- OPTION-VMS (NCT06049797)
- Testing
- Fezolinetant, Paroxetine, Citalopram
- Where
- 48 sites in United States
- Volunteers
- 999 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cancer
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
RATIONALE: Liposomal amphotericin B may be effective in controlling fever and granulocytopenia. It is not yet known which regimen of liposomal amphotericin B is more effective in treating cancer patients who have these…
- Trial name
- NCT00003938
- Testing
- liposomal amphotericin B
- Where
- 24 sites in Belgium, Czechia and 13 more
- Volunteers
- 115 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hidradenitis Suppurativa
Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa
This study is an open-label, dose-escalation study enrolling 15 participants. There are 3 cohorts: 1. Cohort I: 5 subjects each receiving 1 injection of IGN-AMP001 (12.5mg AMP-001 in 3ml Saline) 2.
- Trial name
- NCT04541550
- Testing
- AMP-001 Low Dose, AMP-001 Medium Dose, AMP-001 High Dose
- Where
- United States
- Sponsor
- IntegoGen, LLC
Hidradenitis Suppurativa
Defects of Keratinocytes Function in Dermatologic Patients
NOTCH signaling in the skin exerts a pivotal role in the regulation of normal keratinocytes turnover by mediating the balance between proliferation, differentiation, apoptosis and autophagic flux progression.
- Trial name
- NCT06324552
- Where
- 15 sites in Austria, Belgium and 4 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- IRCCS Burlo Garofolo
Hidradenitis Suppurativa
Safety and Treatment of Cryoinsufflation in Treatment of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic, socially and cosmetically debilitating disease. It typically manifests as nodules and abscesses that ultimately can progress to form deep sinus tracts, fistulas, and scarring.
- Trial name
- NCT05830149
- Testing
- Cryoinsufflation, Deroofing
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Henry Ford Health System
Hidradenitis Suppurativa
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa.
- Trial name
- BRIGHTEN (NCT07170917)
- Testing
- Brivekimig
- Where
- 85 sites in United States, Australia and 17 more
- Volunteers
- 208 people
- Sponsor
- Sanofi
Sweat Analysis
NBA G-League Sweat Testing Study: Validity of the Gx Sweat Patch in Measuring Sweating Rate and Sweat Chloride Concentration During On-court Training With Basketball Players
To determine the validity of the Gx Sweat Patch in measuring sweating rate and sweat chloride concentration during moderate-high intensity practice against well-established reference methods in field conditions with basketball…
- Trial name
- NCT04679532
- Testing
- Gx sweat patch, Reference sweat patch
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Cystic Fibrosis
Efficacy of a New Sweat Collection Support: Impact on Neonatal Screening and Early Treatment of Cystic Fibrosis
In nearly 25% of children under 3 months, the sweat test produces a quantity of sweat that does not meet international recommendations and is insufficient to allow reliable and reproducible biological analyzes in the sweat…
- Trial name
- MACRODUCT-3710 (NCT03913507)
- Testing
- Macroduct® Advanced Model 3710 SYS, Wescor
- Where
- Belgium
- Volunteers
- 57 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain